Effect of lentivirus-mediated survivin transfection on the morphology and apoptosis of nucleus pulposus cells derived from degenerative human disc in vitro.

Effect of Survivin gene therapy via lentivirus vector on the course of intervertebral disc degeneration in an in vivo rabbit model. Mol Med Rep (2016) 0.75

Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976) (2000) 4.39

The Epidemiology of low back pain. Best Pract Res Clin Rheumatol (2010) 3.96

Aging and degeneration of the human intervertebral disc. Spine (Phila Pa 1976) (1995) 3.93

The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther (2005) 3.47

Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine (Phila Pa 1976) (2004) 2.67

Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem (1999) 2.52

Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans (2007) 2.36

Low back pain: a twentieth century health care enigma. Spine (Phila Pa 1976) (1996) 2.29

The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain. Rheumatology (Oxford) (2008) 2.28

Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs. Mol Pathol (2002) 2.23

Structural, functional and therapeutic biology of survivin. Cancer Lett (2006) 1.91

The origin of chondrocytes in the nucleus pulposus and histologic findings associated with the transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus in intact rabbit intervertebral discs. Spine (Phila Pa 1976) (2003) 1.91

1997 Volvo Award winner in basic science studies. Immunohistologic markers for age-related changes of human lumbar intervertebral discs. Spine (Phila Pa 1976) (1997) 1.75

Degeneration and regeneration of the intervertebral disc: lessons from development. Dis Model Mech (2010) 1.69

Prevalence of low back pain in the community: implications for service provision in Bradford, UK. J Epidemiol Community Health (1996) 1.62

The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother (2009) 1.60

The universal character of the tumor-associated antigen survivin. Clin Cancer Res (2007) 1.50

Intervertebral disc degeneration: the role of the mitochondrial pathway in annulus fibrosus cell apoptosis induced by overload. Am J Pathol (2004) 1.49

Human anulus fibrosis and nucleus pulposus cells of the intervertebral disc: effect of degeneration and culture system on cell phenotype. Spine (Phila Pa 1976) (2005) 1.32

Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol (2004) 1.30

Molecular pathogenic factors in symptomatic disc degeneration. Spine J (2005) 1.27

Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med (2013) 1.26

Age-related changes in the extracellular matrix of nucleus pulposus and anulus fibrosus of human intervertebral disc. Spine (Phila Pa 1976) (2009) 1.19

Interleukin-1beta enhances the effect of serum deprivation on rat annular cell apoptosis. Apoptosis (2007) 1.10

Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood (2005) 1.10

Fas ligand expression on human nucleus pulposus cells decreases with disc degeneration processes. J Orthop Sci (2008) 1.09

The experience of back pain in young Australians. Man Ther (2001) 1.07

Low back disability. A syndrome of Western civilization. Neurosurg Clin N Am (1991) 1.02

Biochemical composition and turnover of the extracellular matrix of the normal and degenerate intervertebral disc. Eur Spine J (2013) 0.98

Fas/FasL interaction of nucleus pulposus and cancer cells with the activation of caspases. Int Orthop (2007) 0.94

MAPK pathway activation delays G2/M progression by destabilizing Cdc25B. J Biol Chem (2009) 0.92

Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res (2012) 0.92

Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med (2009) 0.91

Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep (2010) 0.90

Genistein induces morphology change and G2/M cell cycle arrest by inducing p38 MAPK activation in macrophages. Int Immunopharmacol (2013) 0.86

Mechanical stress-induced apoptosis of nucleus pulposus cells: an in vitro and in vivo rat model. J Orthop Sci (2013) 0.86

Pathological survivin expression links viral infections with pathogenesis of erosive rheumatoid arthritis. Scand J Immunol (2007) 0.85

Lindane and cell death: at the crossroads between apoptosis, necrosis and autophagy. Toxicology (2008) 0.83

Epidemiology of low back pain: what's new? Joint Bone Spine (2009) 0.83

Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol Oncol (2013) 0.82

[Survivin in cancerology : molecular aspects and therapeutic applications]. Med Sci (Paris) (2008) 0.81

The oncofetal gene survivin is re-expressed in osteoarthritis and is required for chondrocyte proliferation in vitro. BMC Musculoskelet Disord (2011) 0.81

Apoptosis in the sequestrated nucleus pulposus compared to the remaining nucleus pulposus in the same patient. Spine (Phila Pa 1976) (2011) 0.80

Gene therapy for disc repair. Spine J (2005) 0.79